PolyPid_logo.jpg
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market
June 05, 2023 16:02 ET | PolyPid Ltd.
PETACH TIKVA, Israel, June 05, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
ErascaTM_Logo.png
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
June 05, 2023 16:01 ET | Erasca, Inc.
ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC showed a 50% (3/6) response rate (2 cPR, 1 uPR), reinforcing ERAS-007 as a potential best-in-class ERK...
HealthEquitylogo-purple 2020.jpg
HealthEquity Reports First Quarter Ended April 30, 2023 Financial Results
June 05, 2023 16:01 ET | HealthEquity, Inc.
Highlights of the first quarter include: Revenue of $244.4 million, an increase of 19% compared to $205.7 million in Q1 FY23.Net income of $4.1 million, compared to net loss of $13.6 million in Q1...
Ocular Logo.png
Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
June 05, 2023 16:01 ET | Ocular Therapeutix, Inc.
BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Intellia.jpg
Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
June 05, 2023 16:01 ET | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics...
logo.jpg
Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares
June 05, 2023 16:01 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent...
ultragenyx-CMYK.png
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
June 05, 2023 16:00 ET | Ultragenyx Pharmaceutical Inc.
Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning to...
Arcutis logo.png
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2023 16:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
BOKF logo.jpg
Bank of Texas enters San Antonio market
June 05, 2023 16:00 ET | BOK Financial Corporation
SAN ANTONIO, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Bank of Texas is proud to expand its operations into the San Antonio market, the first outside of the bank’s established operations in Dallas,...
PDS Biotech Logo.png
PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
June 05, 2023 14:52 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...